# Pulmatrix, Inc.

## Overview

**Symbol**: PULM  
**Exchange**: NASDAQ  
**Current Price**: $1.26  
**Change**: +$0.02 (1.61%)

### Recent Price Information
- **At close**: Apr 30, 4:00:00 PM EDT
- **After-hours**: Apr 30, 4:00:26 PM EDT

## Stories & Analysis

- **[No China sales cut Pulmonx revenue 9%, but 2026 forecast holds](https://www.stocktitan.net/news/LUNG/pulmonx-reports-first-quarter-2026-financial-5lekzdnacju6.html)**  
  Stock Titan · Apr 28, 2026

- **[Eos-backed investor takes 9.99% Pulmatrix (PULM) stake ahead merger](https://www.stocktitan.net/sec-filings/PULM/schedule-13d-pulmatrix-inc-major-shareholder-acquisition-5-e74ca12c962d.html)**  
  Stock Titan · Apr 21, 2026

- **[Pulmatrix announces closing of preferred stock transaction as part of planned merger](https://www.marketscreener.com/news/pulmatrix-announces-closing-of-preferred-stock-transaction-as-part-of-planned-merger-ce7f59dbdb8bf121)**  
  marketscreener.com · Apr 20, 2026

- **[A $1M cash infusion gives Pulmatrix working capital as Eos merger advances](https://www.stocktitan.net/news/PULM/pulmatrix-announces-closing-of-preferred-stock-transaction-as-part-647oo1qu1zsn.html)**  
  Stock Titan · Apr 20, 2026

## Key Issues

### Merger with Eos SENOLYTIX: Strategic opportunity or risky pivot?

#### Bullish view
The planned merger with Eos SENOLYTIX, backed by the closing of the Series B Convertible Preferred Stock transaction, signals a concrete strategic step forward. The CEO described it as 'an important initial step forward,' suggesting management confidence in the deal's potential to unlock new value for shareholders.

#### Bearish view
The merger raises serious execution risks. The $1M raised is a modest capital infusion, and the $2.20 conversion price is significantly above the current stock price of $1.34, pointing to deep dilution concerns. The company's ability to complete the transaction and maintain Nasdaq compliance remains highly uncertain.

## Company Information

- **Symbol**: PULM  
- **IPO Date**: Mar 20, 2014  
- **CEO**: Peter Ludlum  
- **Fulltime Employees**: 2  
- **Sector**: Healthcare  
- **Industry**: Biotechnology  
- **Country**: United States

## Earnings History

### EPS Revenue
| Quarter      | Estimate | Beat | Miss | Match |
|--------------|----------|------|------|-------|
| Q2 '22      | -$1.50   | -    | -    | -     |
| Q3 '22      | -$1.00   | -    | -    | -     |
| Q4 '22      | -$0.50   | -    | -    | -     |
| Q1 '23      | $0.00    | -    | -    | -     |
| Q2 '23      | $0.50    | -    | -    | -     |

---